Akebia Therapeutics traded at $1.45 this Tuesday May 5th, decreasing $0.05 or 3.33 percent since the previous trading session. Looking back, over the last four weeks, Akebia Therapeutics lost 9.85 percent. Over the last 12 months, its price fell by 37.50 percent. Looking ahead, we forecast Akebia Therapeutics to be priced at 1.37 by the end of this quarter and at 1.29 in one year, according to Trading Economics global macro models projections and analysts expectations.
Akebia Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on producing medicines for people living with kidney disease. Its lead product candidate, vadadustat, is an oral therapy in development for the treatment of anemia due to chronic kidney disease (CKD). Vadadustat is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI), designed to mimic the physiologic effect of altitude on oxygen availability. In addition, it has a commercial product, Auryxia (ferric citrate), which is marketed for two indications in the United States: the control of serum phosphorus levels in adult patients with dialysis-dependent (DD)-CKD or the hyperphosphatemia indication, and the treatment of iron deficiency anemia (IDA), in adult patients with non-dialysis dependent (NDD)-CKD or the IDA indication. Its ferric citrate is also approved and marketed in Japan as an oral treatment for the improvement of hyperphosphatemia in patients with CKD.